These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. Gómez G; Alvarez ML; Errasti P; Lavilla FJ; García N; Ballester B; García I; Purroy A Transplant Proc; 1999 Sep; 31(6):2250-1. PubMed ID: 10500563 [No Abstract] [Full Text] [Related]
5. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? Morozumi K; Sugito K; Oda A; Takeuchi O; Fukuda M; Usami T; Oikawa T; Fujinami T; Koyama K; Takeda A; Yoshida A; Haba T; Tominaga Y; Uchida K; Yokoyama I; Takagi H Transplant Proc; 1996 Apr; 28(2):1076-8. PubMed ID: 8623232 [No Abstract] [Full Text] [Related]
6. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386 [No Abstract] [Full Text] [Related]
7. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Friemann S; Feuring E; Padberg W; Ernst W Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504 [No Abstract] [Full Text] [Related]
8. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Morales JM; Andres A; Rengel M; Rodicio JL Nephrol Dial Transplant; 2001; 16 Suppl 1():121-4. PubMed ID: 11369839 [TBL] [Abstract][Full Text] [Related]
9. Histopathologic findings in routine biopsies of renal transplant allografts. Toki K; Kyo M; Takahara S; Hatori M; Morozumi K; Ichimaru N; Wang JD; Ding XQ; Miyamoto M; Oka K; Kyakuno M; Kojima Y; Kokado Y; Okuyama A Transplant Proc; 1999 Sep; 31(6):2655-8. PubMed ID: 10500759 [No Abstract] [Full Text] [Related]
10. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). Wilczek HE; Brattström C; Reinholt FP; Tydén G; Ericzon BG Transplant Proc; 1996 Dec; 28(6):3177. PubMed ID: 8962232 [No Abstract] [Full Text] [Related]
11. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. Scheel AK; Blaschke S; Schettler V; Mayer C; Müller GA; Bittermann HJ; Grunewald RW Transplant Proc; 2001; 33(7-8):3693-4. PubMed ID: 11750573 [No Abstract] [Full Text] [Related]
13. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235 [TBL] [Abstract][Full Text] [Related]
14. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Cronin DC; Bruce DS; Newell KA; Josephson MA; Millis JM; Piper JB; Ruebe M; Kirby M; Thistlethwaite JR; Woodle ES Transplant Proc; 1997; 29(1-2):307. PubMed ID: 9123010 [No Abstract] [Full Text] [Related]